Table 4.
Multivariate analysis of EFS and OS in chemotherapy-only group and allo-HSCT group.
Variables | EFS | OS | |||
---|---|---|---|---|---|
HR(95%CI) | P-value | HR(95%CI) | P-value | ||
Chemotherapy-only group | |||||
SPNS2 | 3.072 (1.378-6.851) | 0.006 | 1.884 (1.006-3.526) | 0.048 | |
SPNS3 | 1.525 (0.737-3.156) | 0.225 | 1.287 (0.728-2.276) | 0.386 | |
PB (≥20 vs. <20 × 10%) | 0.680 (0.341-1.359) | 0.275 | 0.653 (0.374-1.140) | 0.134 | |
FLT3-ITD (positive vs. negative) | 0.889 (0.398-1.988) | 0.775 | 0.863 (0.443-1.681) | 0.666 | |
NPM1 (mutated vs. wild) | 0.870 (0.398-1.948) | 0.736 | 0.875 (0.473-1.617) | 0.670 | |
DNMT3A (mutated vs. wild) | 1.265 (0.595-2.687) | 0.541 | 1.626 (0.920-2.871) | 0.094 | |
TET2 (mutated vs. wild) | 0.476 (0.161-1.410) | 0.180 | 0.619 (0.296-1.294) | 0.202 | |
Allo-HSCT | |||||
SPNS3 | 1.092 (0.289-4.126) | 0.897 | 2.789 (1.257-5.339) | 0.002 | |
Age (≥60 vs. <60 years) | 0.740 (0.235-2.331) | 0.607 | 1.061 (0.560-2.010) | 0.856 | |
PB (≥20 vs. <20 × 10%) | 0.428 (0.149-1.227) | 0.114 | 0.774 (0.404-1.481) | 0.439 | |
FLT3-ITD (positive vs. negative) | 2.068 (0.450-9.508) | 0.351 | 2.359 (1.062-5.240) | 0.035 | |
NPM1 (mutated vs. wild) | 0.597 (0.132-2.697) | 0.502 | 0.502 (0.214-1.174) | 0.112 | |
IDH1/IDH2 (mutated vs. wild) | 1.456 (0.407-5.204) | 0.563 | 0.789 (0.364-1.707) | 0.547 | |
RUNX1(mutated vs. wild) | 2.275 (0.415-12.468) | 0.344 | 1.529 (0.614-3.807) | 0.361 |
EFS event-free survival, OS overall survival, HR hazard ratio, CI confidential interval, PB peripheral blood